EA201070108A1 - Cd44 сплайс-варианты в нейродегенеративных заболеваниях - Google Patents
Cd44 сплайс-варианты в нейродегенеративных заболеванияхInfo
- Publication number
- EA201070108A1 EA201070108A1 EA201070108A EA201070108A EA201070108A1 EA 201070108 A1 EA201070108 A1 EA 201070108A1 EA 201070108 A EA201070108 A EA 201070108A EA 201070108 A EA201070108 A EA 201070108A EA 201070108 A1 EA201070108 A1 EA 201070108A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seq
- splice
- options
- neurodegenerative diseases
- homologous
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 102100032912 CD44 antigen Human genes 0.000 title 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 229920002477 rna polymer Polymers 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92970607P | 2007-07-10 | 2007-07-10 | |
| PCT/IB2008/052786 WO2009007934A2 (en) | 2007-07-10 | 2008-07-10 | Cd44 splice variants in neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201070108A1 true EA201070108A1 (ru) | 2010-06-30 |
Family
ID=40229192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201070108A EA201070108A1 (ru) | 2007-07-10 | 2008-07-10 | Cd44 сплайс-варианты в нейродегенеративных заболеваниях |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9018180B2 (enExample) |
| EP (1) | EP2167692B1 (enExample) |
| JP (1) | JP2010532989A (enExample) |
| KR (1) | KR20100044793A (enExample) |
| CN (1) | CN101821407B (enExample) |
| AU (1) | AU2008273713B2 (enExample) |
| BR (1) | BRPI0814685A2 (enExample) |
| CA (1) | CA2692861A1 (enExample) |
| EA (1) | EA201070108A1 (enExample) |
| ES (1) | ES2423182T3 (enExample) |
| IL (1) | IL203130A (enExample) |
| MX (1) | MX2010000236A (enExample) |
| NZ (1) | NZ582390A (enExample) |
| WO (1) | WO2009007934A2 (enExample) |
| ZA (1) | ZA201000083B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| EP2531502B1 (en) | 2010-02-01 | 2014-04-02 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| JP5960793B2 (ja) | 2011-03-24 | 2016-08-02 | ニューリム ファーマシューティカルズ（１９９１）リミテッド | 神経保護ペプチド |
| US9399779B2 (en) * | 2011-06-08 | 2016-07-26 | The Corporation Of Mercer University | Alternative splicing constructs and methods of use |
| CN104277092B (zh) * | 2013-07-12 | 2017-10-31 | 天津医科大学 | 用于预防和/或治疗老年性痴呆的β片层阻断肽 |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| US10400009B2 (en) | 2014-09-04 | 2019-09-03 | Tianjin Medical University | β-sheet breaker peptide used for preventing and/or treating alzheimer's disease |
| CN107815438A (zh) * | 2017-08-02 | 2018-03-20 | 清华大学 | 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物 |
| MX2023013420A (es) | 2021-05-11 | 2023-12-06 | Neurim Pharmaceuticals 1991 Ltd | Metodo para diagnosticar y tratar sujetos que tienen polimorfismos de un solo nucleotido en el cromosoma 2, locus 2:107,510,000-107,540,000. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990299A (en) * | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6150162A (en) | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| IL133647A0 (en) * | 1999-06-08 | 2001-04-30 | Yissum Res Dev Co | Novel cd44 variant |
| US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| RU2322500C2 (ru) * | 2000-12-01 | 2008-04-20 | Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. | Малые молекулы рнк, опосредующие интерференцию рнк |
| CA2439630A1 (en) | 2001-03-23 | 2002-10-03 | Agy Therapeutics | Use of biomolecular targets in the treatment and visualization of brain tumors |
| CN1511040A (zh) | 2001-05-25 | 2004-07-07 | ����˹���ѷ��ѧ | 作为多种治疗模式基础的蛋白质的选择性剪接形式 |
| US7833779B2 (en) * | 2001-07-25 | 2010-11-16 | Jivan Biologies Inc. | Methods and systems for polynucleotide detection |
| EP1670943B1 (en) * | 2003-09-30 | 2013-11-13 | Evotec International GmbH | Diagnostic and therapeutic use of a sulfotransferase for alzheimer's disease |
| ATE495269T1 (de) * | 2005-06-16 | 2011-01-15 | Evotec Neurosciences Gmbh | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen |
-
2008
- 2008-07-10 AU AU2008273713A patent/AU2008273713B2/en active Active
- 2008-07-10 ES ES08776569T patent/ES2423182T3/es active Active
- 2008-07-10 MX MX2010000236A patent/MX2010000236A/es active IP Right Grant
- 2008-07-10 JP JP2010515648A patent/JP2010532989A/ja active Pending
- 2008-07-10 CA CA 2692861 patent/CA2692861A1/en not_active Abandoned
- 2008-07-10 KR KR1020107001642A patent/KR20100044793A/ko not_active Ceased
- 2008-07-10 EA EA201070108A patent/EA201070108A1/ru unknown
- 2008-07-10 BR BRPI0814685A patent/BRPI0814685A2/pt not_active IP Right Cessation
- 2008-07-10 US US12/668,563 patent/US9018180B2/en active Active
- 2008-07-10 CN CN2008801049431A patent/CN101821407B/zh active Active
- 2008-07-10 WO PCT/IB2008/052786 patent/WO2009007934A2/en not_active Ceased
- 2008-07-10 NZ NZ582390A patent/NZ582390A/en not_active IP Right Cessation
- 2008-07-10 EP EP08776569.9A patent/EP2167692B1/en active Active
-
2010
- 2010-01-04 IL IL203130A patent/IL203130A/en not_active IP Right Cessation
- 2010-01-05 ZA ZA2010/00083A patent/ZA201000083B/en unknown
-
2015
- 2015-03-27 US US14/671,281 patent/US9416166B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9018180B2 (en) | 2015-04-28 |
| WO2009007934A3 (en) | 2009-05-07 |
| BRPI0814685A2 (pt) | 2019-09-24 |
| ES2423182T3 (es) | 2013-09-18 |
| US9416166B2 (en) | 2016-08-16 |
| HK1145856A1 (en) | 2011-05-06 |
| ZA201000083B (en) | 2011-03-30 |
| AU2008273713B2 (en) | 2014-07-03 |
| EP2167692B1 (en) | 2013-05-22 |
| US20150266940A1 (en) | 2015-09-24 |
| CA2692861A1 (en) | 2009-01-15 |
| WO2009007934A2 (en) | 2009-01-15 |
| MX2010000236A (es) | 2010-06-02 |
| IL203130A (en) | 2014-07-31 |
| EP2167692A2 (en) | 2010-03-31 |
| KR20100044793A (ko) | 2010-04-30 |
| NZ582390A (en) | 2012-05-25 |
| JP2010532989A (ja) | 2010-10-21 |
| US20110172286A1 (en) | 2011-07-14 |
| CN101821407A (zh) | 2010-09-01 |
| AU2008273713A1 (en) | 2009-01-15 |
| CN101821407B (zh) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201070108A1 (ru) | Cd44 сплайс-варианты в нейродегенеративных заболеваниях | |
| AU2019357450B2 (en) | Methods and compositions for editing RNAs | |
| EA201071323A1 (ru) | Axmi-115, axmi-113, axmi-005, axmi-163, axmi-184 инсектицидные белки и способы их применения | |
| JP2002272489A5 (enExample) | ||
| WO2020205605A3 (en) | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 | |
| BR112014001909A2 (pt) | gene da toxina axmi270 e métodos para a sua utilização | |
| WO2009150222A3 (en) | Improved protein expression system | |
| NZ602352A (en) | Toxin genes and methods for their use | |
| EA201300054A1 (ru) | Полипептид, обладающий активностью бета-глюкозидазы, и его применение | |
| EA201170685A1 (ru) | Гены, кодирущие токсины нематод | |
| JP2016520320A5 (enExample) | ||
| WO2007134272A3 (en) | Humanized models via targeted mtagenesis with zinc finger nuclease | |
| DE502007003734D1 (de) | Verfahren zur enzymatischen herstellung von 2-hydroxy-2-methylcarbonsäuren | |
| BR112014001978A2 (pt) | proteínas variantes axmi205 e métodos para a utilização das mesmas | |
| WO2007117438A3 (en) | Methods for the production of functional protein from dna having a nonsense mutation and the treatment of disorders associated therewith | |
| MX2009000656A (es) | Acidos nucleicos que se fijan a sdf-i. | |
| WO2010011283A3 (en) | Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases | |
| ATE528008T1 (de) | Rnai-modulation von aha und ihre therapeutische verwendung | |
| WO2010060967A3 (en) | Compositions and methods for treating retrovirus infections | |
| EP3924048A1 (en) | Myc, cyclin t1 and/or cdk9 for use in the treatment of degenerative heart and cns disorders | |
| JP2018537089A5 (enExample) | ||
| UA122856C2 (uk) | Варіантний інсектицидний ген ахмі115 та способи його застосування | |
| ATE536745T1 (de) | Zusammensetzung mit arazym zur prävention und behandlung von krebs | |
| Sundaramoorthi et al. | Knockdown of αIIb by RNA degradation by delivering deoxyoligonucleotides piggybacked with control vivo-morpholinos into zebrafish thrombocytes | |
| BR112012010537A2 (pt) | "clonagem, expressão e uso de fosfolipases ácidas" |